FEV Inhibitors
FEV inhibitors belong to a class of chemical compounds designed to target and modulate the activity of the FEV protein, also known as ETS family Variant gene 4. FEV is a transcription factor that is a member of the ETS (E26 transformation-specific) transcription factor family, which plays crucial roles in gene regulation, particularly in controlling cell differentiation and development. FEV is known to be expressed in specific tissues, including the brain, lung, and gastrointestinal tract, and is involved in various developmental processes. Inhibitors of FEV are developed to interfere with its transcriptional regulatory functions or other activities, potentially affecting the gene expression patterns and cellular processes governed by this protein.
The mechanisms by which FEV inhibitors function can vary based on their chemical structures and binding properties. Some inhibitors may directly interact with FEV, preventing its binding to specific DNA sequences or the recruitment of co-regulatory proteins necessary for transcriptional activation or repression. Others may modulate the stability or conformation of FEV, affecting its ability to regulate the expression of target genes. By inhibiting FEV, these compounds have the potential to influence the transcriptional programs and developmental pathways regulated by this transcription factor, particularly in tissues where FEV is highly expressed. Ongoing research in this field aims to elucidate the precise mechanisms and downstream effects of FEV inhibition, contributing to our understanding of its role in cellular biology and development.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Antagonizes aldosterone receptors affecting gene regulation, potentially influencing FEV transcription. | ||||||
Mifepristone | 84371-65-3 | sc-203134 | 100 mg | $61.00 | 17 | |
Glucocorticoid and progesterone receptor antagonist that may alter various gene expressions, including FEV. | ||||||
Mitotane | 53-19-0 | sc-205754 sc-205754A | 100 mg 1 g | $72.00 $166.00 | 1 | |
Adrenolytic activity may lead to altered steroidogenesis, thereby indirectly affecting FEV transcriptional regulation. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
HDAC inhibitor that may change chromatin accessibility, potentially decreasing FEV gene transcription. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
DNA methyltransferase inhibitor that can reactivate silenced genes, possibly influencing FEV expression. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $186.00 $674.00 | 10 | |
Disrupts the function of HIF-1 transcriptional complex, potentially affecting FEV gene regulation. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Cyclin-dependent kinase inhibitor that may alter cell cycle-dependent gene expression, including FEV. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Glycogen synthase kinase-3 (GSK-3) inhibitor that may impact Wnt signaling and downstream gene expression, such as FEV. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $61.00 $153.00 $231.00 $505.00 | 1 | |
Another GSK-3 inhibitor with potential effects on gene expression including the FEV gene. | ||||||
Oligomycin A | 579-13-5 | sc-201551 sc-201551A sc-201551B sc-201551C sc-201551D | 5 mg 25 mg 100 mg 500 mg 1 g | $179.00 $612.00 $1203.00 $5202.00 $9364.00 | 26 | |
Inhibits the mitochondrial ATP synthase, potentially impacting cell metabolism and gene expression, including FEV. | ||||||